Lookup NU author(s): Professor Mike Waring
This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Chemical Society, 2017.
For re-use rights please refer to the publisher's terms and conditions.
Inhibition of the protein-protein interaction between B-cell lymphoma 6 (BCL6) and corepressors has been implicated as a therapeutic target in diffuse large B-cell lymphoma (DLBCL) cancers and profiling of potent and selective BCL6 inhibitors are critical to test this hypothesis. We identified a pyrazolo[1,5-a]pyrimidine series of BCL6 binders from a fragment screen in parallel with a virtual screen. Using structure based drug design, binding affinity was increased 100,000-fold. This involved displacing crystallographic water, forming new ligand-protein interactions and a macrocyclization to favor the bioactive conformation of the ligands. Optimization for slow off-rate constant kinetics was conducted as well as improving selectivity against an off-target kinase, CK2. Potency in a cellular BCL6 assay was further optimized to afford highly selective probe molecules. Only weak anti-proliferative effects were observed across a number of DLBCL lines and a multiple myeloma cell line without a clear relationship to BCL6 potency. As a result we conclude that the BCL6 hypothesis in DLBCL cancer remains unproven.
Author(s): McCoull W, Abrams RD, Anderson E, Blades K, Barton P, Box M, Burgess J, Byth K, Cao Q, Chuaqui C, Carbajo RJ, Cheung T, Code E, Ferguson AD, Fillery S, Fuller NO, Gangl E, Gao N, Grist M, Hargreaves D, Howard MR, Hu J, Kemmitt PD, Nelson JE, OConnell N, Prince DB, Raubo P, Rawlins PB, Robb GR, Shi J, Waring MJ, Whittaker D, Wylot M, Zhu X
Publication type: Article
Publication status: Published
Journal: Journal of Medicinal Chemistry
Print publication date: 25/05/2017
Online publication date: 09/05/2017
Acceptance date: 08/05/2017
Date deposited: 09/05/2017
ISSN (print): 0022-2623
ISSN (electronic): 1520-4804
Publisher: American Chemical Society
Altmetrics provided by Altmetric